BIOGEN MA INC. Patent applications |
Patent application number | Title | Published |
20160131634 | METHODS OF EVALUATING CELL CULTURE ADDITIVES - The present disclosure shows, unexpectedly, that variations in cell culture performance in large-scale cell culture systems such as, for example, those used in commercial manufacturing processes, in some instances, can be attributed to often subtle variations among shear-protectant additives used during cell culture. Assessing the quality of shear-protective additives using such large-scale systems, however, is inaccurate, time-consuming and costly. To solve the problem identified, the present disclosure provides methods and compositions for evaluating the suitability of shear-protectant additives without resorting to large scale cell growth and/or protein production tests. | 05-12-2016 |
20160130361 | ANTI-FACTOR VIII ANTIBODIES OR USES THEREOF - The present invention provides anti-FVIII antibodies and antigen-binding molecules thereof which specifically bind FVIII epitopes. The antibodies and antigen-binding molecules can be used to purify FVIII. The invention also includes nucleic acid molecules and methods of making the anti-FVIII antibodies or antigen binding molecules thereof. | 05-12-2016 |
20160115467 | CHIMERIC FVII-XTEN MOLECULES AND USES THEREOF - The present invention provides chimeric FVII molecules comprising FVII, an XTEN polypeptide, and an antibody C and antigen-binding molecules thereof which specifically bind the α and/or β subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties, e.g., half-life extending moiety. The invention also includes methods of producing and using the chimeric molecules. | 04-28-2016 |
20160030604 | COMPOSITIONS AND METHODS FOR ASSESSING NEUROMUSCULAR FUNCTION - The invention provides compositions and methods for evaluating neuromuscular function in a subject, e.g., a subject at risk for or suffering from a neuromuscular disorder. | 02-04-2016 |
20160029983 | ASSESSMENT OF LABELED PROBES IN A SUBJECT - Wearable apparatus and method of using same for tracking a labeled probe in a subject are disclosed. | 02-04-2016 |
20160025633 | USE OF RAMAN SPECTROSCOPY TO MONITOR CULTURE MEDIUM - In one aspect, the disclosure provides a method of defining a Raman signature of a culture component, the method comprising: obtaining a Raman spectrum of a culture component in a non-interfering or minimally-interfering solution, identifying peaks in the Raman spectrum that are associated with the culture component, obtaining a Raman spectrum of a culture medium comprising the culture component, and, removing peaks of the culture component in the Raman spectrum of the culture medium that are distorted compared to the peaks identified in the Raman spectrum of the culture component in a non-interfering or minimally-interfering solution. | 01-28-2016 |
20160024145 | HYDROPHOBIC INTERACTION PROTEIN CHROMATOGRAPHY UNDER NO-SALT CONDITIONS - Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions. | 01-28-2016 |
20160002743 | HIGH RESOLUTION MELTING ANALYSIS ASSAY FOR THE DETECTION OF VIRAL DNA - In one aspect, the disclosure provides methods, kits and compositions for determining the presence of a JC virus mutant in a sample. | 01-07-2016 |
20160002265 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES - Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein i.a. Ring A is phenylene or 5- to 6-membered heteroarylene; Ring B is phenylene, 5- to 6-membered heterocycloalkylene or 5- to 6-membered heteroarylen; R | 01-07-2016 |
20160000888 | FACTOR IX POLYPEPTIDE FORMULATIONS - The present invention provides formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide, and methods of administering FIXFBP. | 01-07-2016 |
20150361417 | ASSAY FOR DETECTION OF JC VIRUS DNA - In one aspect, the disclosure provides methods for isolating nucleic acid from a Cerebrospinal Fluid (CSF) sample. In one aspect, the disclosure provides methods for determining the amount of JC virus DNA in a sample. | 12-17-2015 |
20150361158 | Optimized Factor VIII Gene - The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. | 12-17-2015 |
20150329638 | Use of DR6 Antagonists to Improve Motor Neuron Disease - The present invention relates to Death Receptor-6 (DR6) antagonists and methods of their use in improving motor neuron disease. Novel affinity enhanced anti-DR6 antibodies are also provided. The invention also pertains to methods of identifying additional anti-DR6 antagonists. | 11-19-2015 |
20150299323 | ANTIBODIES TO VLA-1 - Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures. | 10-22-2015 |
20150266943 | FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF - The present invention includes a chimeric protein comprising a VWF protein with D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain of a VWF fragment is associated with a FVIII polypeptide chain linked to an XTEN sequence. The VWF fragment polypeptide chain can prevent or inhibit binding of endogenous VWF to FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to FVIII protein, VWF fragment can extend half-life of chimeric protein comprising FVIII protein. The invention includes nucleotides, vectors, host cells, use of VWF fragment, or chimeric proteins. | 09-24-2015 |